Amedisys Inc (AMED) 50.91 $AMED
Amedisys Brings In David B. Pearce As New Chief Compliance Officer
GlobeNewswire - Fri Jun 17, 7:00AM CDT
David B. Pearce will join Amedisys, Inc. (NASDAQ:AMED), as Senior Vice President and Chief Compliance Officer, effective July 5.
AMED: 50.91 (+1.60)
38.5% Return Seen to Date on SmarTrend Amedisys Call (AMED)
Comtex SmarTrend(R) - Mon Jun 13, 1:09PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 4 months, Amedisys has returned 38.55% as of today's recent price of $50.68.
AMED: 50.91 (+1.60)
Shares of AMED Up 43.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 03, 12:51PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 4 months, Amedisys has returned 43.12% as of today's recent price of $52.36.
AMED: 50.91 (+1.60)
Amedisys to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 3:00PM CDT
Amedisys, Inc. (NASDAQ:AMED), one of America's leading healthcare at home companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference in New York, NY on Wednesday, June 8, 2016.
AMED: 50.91 (+1.60)
Uptrend Call Working As Amedisys Stock Rises 39.9% (AMED)
Comtex SmarTrend(R) - Fri May 27, 12:30AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 3 months, Amedisys has returned 39.94% as of today's recent price of $51.19.
AMED: 50.91 (+1.60)
Amedisys Has Returned 37.8% Since SmarTrend Recommendation (AMED)
Comtex SmarTrend(R) - Thu May 19, 12:56PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 3 months, Amedisys has returned 37.75% as of today's recent price of $50.39.
AMED: 50.91 (+1.60)
Amedisys Up 40.8% Since SmarTrend Uptrend Call (AMED)
Comtex SmarTrend(R) - Thu May 12, 12:26AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 3 months, Amedisys has returned 40.76% as of today's recent price of $51.49.
AMED: 50.91 (+1.60)
Amedisys to Present at the Bank of America Merrill Lynch Health Care Conference
GlobeNewswire - Fri May 06, 9:00AM CDT
Amedisys, Inc. (NASDAQ:AMED), one of America's leading healthcare at home companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the 2016 Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV on Tuesday, May 10, 2016.
AMED: 50.91 (+1.60)
Amedisys (AMED) Lags Q1 Earnings, Revenues Top the Mark
Zacks Equity Research - Zacks Investment Research - Fri May 06, 8:56AM CDT
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 33 cents per share in the first quarter of 2016.
BSX: 22.97 (+0.31), AFAM: 43.00 (+0.93), AMED: 50.91 (+1.60), HLS: 40.82 (+0.69)
Amedisys Reports First Quarter Financial Results
GlobeNewswire - Tue May 03, 4:31PM CDT
Amedisys, Inc. (NASDAQ:AMED), a leading home health and hospice company, today reported its financial results for the three-month period ended March 31, 2016.
AMED: 50.91 (+1.60)
Chemed (CHE) Q1 Earnings Miss the Mark, Revenues in Line
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:53AM CDT
Chemed Corp. (CHE) reported first-quarter 2016 adjusted earnings per share (EPS) of $1.53.
CHE: 133.99 (+1.37), AFAM: 43.00 (+0.93), AMED: 50.91 (+1.60), HLS: 40.82 (+0.69)
Amedisys Shares Up 42.1% Since SmarTrend's Buy Recommendation (AMED)
Comtex SmarTrend(R) - Wed Apr 27, 12:19AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 2 months, Amedisys has returned 42.13% as of today's recent price of $51.99.
AMED: 50.91 (+1.60)
Amedisys Announces First Quarter Earnings Release and Conference Call Date
GlobeNewswire - Tue Apr 26, 3:03PM CDT
Amedisys, Inc. (NASDAQ:AMED), one of America's leading home health and hospice care companies, announced today that it will report results for the first quarter ended March 31, 2016 after the market closes on May 3, 2016. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2016.
AMED: 50.91 (+1.60)
Amedisys Welcomes Three New Members To Its Board Of Directors
GlobeNewswire - Tue Apr 26, 8:00AM CDT
Amedisys Inc. (NASDAQ:AMED), a leading home health, hospice and personal care company, today announced the addition of three new members to its Board of Directors.
KND: 11.59 (+0.24), SYBT: 28.72 (+0.54), AMED: 50.91 (+1.60)
Quest Diagnostics (DGX) Q1 Earnings in Line, Volume Up
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:23AM CDT
Quest Diagnostics' (DGX) first-quarter 2016 adjusted earnings per share (EPS) of $1.12 came in line with the Zacks Consensus Estimate.
BSX: 22.97 (+0.31), AFAM: 43.00 (+0.93), DGX: 80.53 (+0.94), AMED: 50.91 (+1.60)
AmSurg Poised on Strategic Buyouts, Rising Costs a Concern
Zacks Equity Research - Zacks Investment Research - Wed Apr 20, 4:46PM CDT
On Apr 18, 2016, we issued an updated research report on Nashville, TN-based AmSurg Corp. (AMSG).
AMSG: 81.67 (+0.64), BSX: 22.97 (+0.31), AFAM: 43.00 (+0.93), AMED: 50.91 (+1.60)
Moving Average Crossover Alert: Amedisys (AMED)
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 9:11AM CDT
Amedisys Inc. (AMED) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
AMED: 50.91 (+1.60)
Amedisys Shares Up 29.0% Since SmarTrend's Buy Recommendation (AMED)
Comtex SmarTrend(R) - Tue Apr 12, 1:43PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 2 months, Amedisys has returned 28.95% as of today's recent price of $47.17.
AMED: 50.91 (+1.60)
Amedisys Poised on Balanced Growth, Strategic Buyouts
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 1:35PM CDT
On Apr 11, 2016, we issued an updated research report on Amedisys Inc. (AMED).
AFAM: 43.00 (+0.93), CSII: 17.90 (+0.36), RMD: 64.08 (+1.75), AMED: 50.91 (+1.60)
Amedisys Brings In David B. Pearce As New Chief Compliance Officer
GlobeNewswire - Fri Jun 17, 7:00AM CDT
David B. Pearce will join Amedisys, Inc. (NASDAQ:AMED), as Senior Vice President and Chief Compliance Officer, effective July 5.
AMED: 50.91 (+1.60)
38.5% Return Seen to Date on SmarTrend Amedisys Call (AMED)
Comtex SmarTrend(R) - Mon Jun 13, 1:09PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 4 months, Amedisys has returned 38.55% as of today's recent price of $50.68.
AMED: 50.91 (+1.60)
Shares of AMED Up 43.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 03, 12:51PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 4 months, Amedisys has returned 43.12% as of today's recent price of $52.36.
AMED: 50.91 (+1.60)
Amedisys to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 3:00PM CDT
Amedisys, Inc. (NASDAQ:AMED), one of America's leading healthcare at home companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference in New York, NY on Wednesday, June 8, 2016.
AMED: 50.91 (+1.60)
Uptrend Call Working As Amedisys Stock Rises 39.9% (AMED)
Comtex SmarTrend(R) - Fri May 27, 12:30AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 3 months, Amedisys has returned 39.94% as of today's recent price of $51.19.
AMED: 50.91 (+1.60)
Amedisys Has Returned 37.8% Since SmarTrend Recommendation (AMED)
Comtex SmarTrend(R) - Thu May 19, 12:56PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 3 months, Amedisys has returned 37.75% as of today's recent price of $50.39.
AMED: 50.91 (+1.60)
Amedisys Up 40.8% Since SmarTrend Uptrend Call (AMED)
Comtex SmarTrend(R) - Thu May 12, 12:26AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 3 months, Amedisys has returned 40.76% as of today's recent price of $51.49.
AMED: 50.91 (+1.60)
Amedisys to Present at the Bank of America Merrill Lynch Health Care Conference
GlobeNewswire - Fri May 06, 9:00AM CDT
Amedisys, Inc. (NASDAQ:AMED), one of America's leading healthcare at home companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the 2016 Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV on Tuesday, May 10, 2016.
AMED: 50.91 (+1.60)
Amedisys (AMED) Lags Q1 Earnings, Revenues Top the Mark
Zacks Equity Research - Zacks Investment Research - Fri May 06, 8:56AM CDT
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 33 cents per share in the first quarter of 2016.
BSX: 22.97 (+0.31), AFAM: 43.00 (+0.93), AMED: 50.91 (+1.60), HLS: 40.82 (+0.69)
Amedisys Reports First Quarter Financial Results
GlobeNewswire - Tue May 03, 4:31PM CDT
Amedisys, Inc. (NASDAQ:AMED), a leading home health and hospice company, today reported its financial results for the three-month period ended March 31, 2016.
AMED: 50.91 (+1.60)
Chemed (CHE) Q1 Earnings Miss the Mark, Revenues in Line
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:53AM CDT
Chemed Corp. (CHE) reported first-quarter 2016 adjusted earnings per share (EPS) of $1.53.
CHE: 133.99 (+1.37), AFAM: 43.00 (+0.93), AMED: 50.91 (+1.60), HLS: 40.82 (+0.69)
Amedisys Shares Up 42.1% Since SmarTrend's Buy Recommendation (AMED)
Comtex SmarTrend(R) - Wed Apr 27, 12:19AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 2 months, Amedisys has returned 42.13% as of today's recent price of $51.99.
AMED: 50.91 (+1.60)
Amedisys Announces First Quarter Earnings Release and Conference Call Date
GlobeNewswire - Tue Apr 26, 3:03PM CDT
Amedisys, Inc. (NASDAQ:AMED), one of America's leading home health and hospice care companies, announced today that it will report results for the first quarter ended March 31, 2016 after the market closes on May 3, 2016. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2016.
AMED: 50.91 (+1.60)
Amedisys Welcomes Three New Members To Its Board Of Directors
GlobeNewswire - Tue Apr 26, 8:00AM CDT
Amedisys Inc. (NASDAQ:AMED), a leading home health, hospice and personal care company, today announced the addition of three new members to its Board of Directors.
KND: 11.59 (+0.24), SYBT: 28.72 (+0.54), AMED: 50.91 (+1.60)
Quest Diagnostics (DGX) Q1 Earnings in Line, Volume Up
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:23AM CDT
Quest Diagnostics' (DGX) first-quarter 2016 adjusted earnings per share (EPS) of $1.12 came in line with the Zacks Consensus Estimate.
BSX: 22.97 (+0.31), AFAM: 43.00 (+0.93), DGX: 80.53 (+0.94), AMED: 50.91 (+1.60)
AmSurg Poised on Strategic Buyouts, Rising Costs a Concern
Zacks Equity Research - Zacks Investment Research - Wed Apr 20, 4:46PM CDT
On Apr 18, 2016, we issued an updated research report on Nashville, TN-based AmSurg Corp. (AMSG).
AMSG: 81.67 (+0.64), BSX: 22.97 (+0.31), AFAM: 43.00 (+0.93), AMED: 50.91 (+1.60)
Moving Average Crossover Alert: Amedisys (AMED)
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 9:11AM CDT
Amedisys Inc. (AMED) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
AMED: 50.91 (+1.60)
Amedisys Shares Up 29.0% Since SmarTrend's Buy Recommendation (AMED)
Comtex SmarTrend(R) - Tue Apr 12, 1:43PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 2 months, Amedisys has returned 28.95% as of today's recent price of $47.17.
AMED: 50.91 (+1.60)
Amedisys Poised on Balanced Growth, Strategic Buyouts
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 1:35PM CDT
On Apr 11, 2016, we issued an updated research report on Amedisys Inc. (AMED).
AFAM: 43.00 (+0.93), CSII: 17.90 (+0.36), RMD: 64.08 (+1.75), AMED: 50.91 (+1.60)
